01—Abstract
Summary
Summary of the 8-K filed February 18, 2025. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported fourth-quarter and full-year 2024 results in a press release furnished as Exhibit 99.1 under Item 2.02 of this 8-K, dated February 18, 2025.
Total revenue for the fourth quarter was $298.0 milliona, up from $230.0 million a year earlier, driven by royalty revenue of $170.4 million (up 40% from $122.1 million) and higher collaborative-agreement revenue. For full-year 2024, total revenue was $1,015.3 million versus $829.3 million in 2023, and royalties were $571.0 million versus $447.9 million. Net income for the full year was $444.1 million and GAAP diluted EPS was $3.43; non-GAAP diluted EPS was $4.23.
Adjusted EBITDA for the year was $632.2 millionb, compared with $426.2 million in 2023. The company reiterated its 2025 guidance, first given January 8, 2025: total revenue of $1,150 million to $1,225 million, royalty revenue of $725 million to $750 million, adjusted EBITDA of $755 million to $805 million, and non-GAAP diluted EPS of $4.95 to $5.35. Management said VYVGART Hytrulo is expected to become the largest dollar growth contributor to royalties in 2025.
The company also noted four ENHANZE approvals in the U.S. and EU during 2024, five new ENHANZE nominations, a European ENHANZE patent extension to 2029, and an accelerated share repurchase of $250.0 millionc entered into in December 2024 under a $750 million program. At December 31, 2024, cash, cash equivalents and marketable securities totaled $596.1 million, up from $336.0 million at year-end 2023, and total stockholders' equity was $363.8 million.
Long-term debt, net, was $1,505.8 milliond. The company said the increase in cash was primarily a result of cash generated from operations.
02—Key points
Key Highlights
- Full-year 2024 total revenue reached a record $1,015.3 million, up from $829.3 million in 2023, and royalty revenue rose to $571.0 million from $447.9 million.
- Fourth-quarter 2024 net income was $137.0 million and GAAP diluted EPS was $1.06, compared with $85.4 million and $0.65 in the fourth quarter of 2023.
- Full-year 2024 adjusted EBITDA was $632.2 million versus $426.2 million in 2023; non-GAAP diluted EPS was $4.23 versus $2.77.
- 2025 guidance was reiterated: total revenue of $1,150–$1,225 million, royalty revenue of $725–$750 million, adjusted EBITDA of $755–$805 million, and non-GAAP diluted EPS of $4.95–$5.35.
- Cash, cash equivalents and marketable securities rose to $596.1 million at December 31, 2024, from $336.0 million a year earlier.
- The company entered into a $250.0 million accelerated share repurchase in December 2024 under a $750 million program approved in February 2024.
- Four ENHANZE approvals in the U.S. and EU in 2024 (VYVGART Hytrulo for CIDP, Tecentriq Hybreza, Ocrevus Zunovo and Opdivo Qvantig), five new ENHANZE nominations, and a European patent extension to 2029 were cited as growth support.
03—Questions
Frequently Asked Questions
How did Halozyme perform in the fourth quarter of 2024?
Total revenue was $298.0 million, up from $230.0 million in the fourth quarter of 2023. Royalty revenue was $170.4 million, up from $122.1 million, and net income was $137.0 million, compared with $85.4 million. GAAP diluted EPS was $1.06 versus $0.65.
What guidance did Halozyme give for 2025?
The company reiterated its 2025 guidance of total revenue of $1,150–$1,225 million, royalty revenue of $725–$750 million, adjusted EBITDA of $755–$805 million, and non-GAAP diluted EPS of $4.95–$5.35. The EPS guidance does not consider potential future share repurchases.
Which products are expected to drive royalty growth in 2025?
Management said DARZALEX SC, Phesgo and VYVGART Hytrulo will continue to drive 2025 royalty revenue, with VYVGART Hytrulo expected to become the largest dollar growth contributor in 2025.
What capital return actions did Halozyme take?
In December 2024, Halozyme entered into an accelerated share repurchase agreement to buy back $250.0 million of common stock under a $750 million program approved in February 2024.
How much cash and marketable securities did Halozyme hold at year-end 2024?
Cash, cash equivalents and marketable securities were $596.1 million at December 31, 2024, compared with $336.0 million at December 31, 2023, which the company attributed primarily to cash generated from operations.
04—Continue